This is a competing renewal application for a Center to prepare adult stem/progenitor cells from the bone marrow of human volunteers and rodents, define the quality of the cells, and then distribute them to multiple investigators. The adult stem/progenitor cells we prepare were originally referred to as fibroblastic colony forming - units, then as marrow stromal cells in the hematological literature, subsequently as mesenchymal stem cells, and most recently as multipotent mesenchymal stromal cells or MSCs. Since its establishment in June of 2003, the Center has made 451 shipments of 1,013 vials of frozen MSCs to 220 individual investigators, 129 of which are NIH funded (Appendix A). An additional 41 investigators have submitted MTAs to receive MSCs;of which 14 are NIH funded. A total of 114 investigators have provided letters of support for this competing renewal application.
The Specific Aims are: 1. To continue to produce standardized preparations of human MSCs (hMSCs) for distribution to other investigators. 2. To continue to provide similarly characterized preparations of rat MSCs (rMSCs) for distribution to other investigators. 3. To continue to provide similar preparations of mouse MSCs (moMSCs) for distribution to other investigators. 4. To develop improved methods for isolating and characterizing hMSCs. The need for experiments with fully characterized MSCs has become critical with the current efforts by us and others to initiate Phase I and Phase II clinical trials with MSCs.

Agency
National Institute of Health (NIH)
Institute
Office of The Director, National Institutes of Health (OD)
Type
Animal (Mammalian and Nonmammalian) Model, and Animal and Biological Material Resource Grants (P40)
Project #
7P40OD011050-10
Application #
8269008
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Program Officer
Mirochnitchenko, Oleg
Project Start
2003-06-01
Project End
2013-06-14
Budget Start
2012-06-01
Budget End
2013-06-14
Support Year
10
Fiscal Year
2012
Total Cost
$1,066,834
Indirect Cost
$338,620
Name
Texas A&M University
Department
None
Type
Schools of Medicine
DUNS #
835607441
City
College Station
State
TX
Country
United States
Zip Code
77845
Bazhanov, Nikolay; Ylostalo, Joni H; Bartosh, Thomas J et al. (2016) Intraperitoneally infused human mesenchymal stem cells form aggregates with mouse immune cells and attach to peritoneal organs. Stem Cell Res Ther 7:27
Prockop, Darwin J (2016) Inflammation, fibrosis, and modulation of the process by mesenchymal stem/stromal cells. Matrix Biol 51:7-13
Mittal, Manish; Tiruppathi, Chinnaswamy; Nepal, Saroj et al. (2016) TNFα-stimulated gene-6 (TSG6) activates macrophage phenotype transition to prevent inflammatory lung injury. Proc Natl Acad Sci U S A 113:E8151-E8158
Xie, Jie; Broxmeyer, Hal E; Feng, Dongni et al. (2015) Human adipose-derived stem cells ameliorate cigarette smoke-induced murine myelosuppression via secretion of TSG-6. Stem Cells 33:468-78
Beltran, Stacy R; Svoboda, Kathy K H; Kerns, David G et al. (2015) Anti-inflammatory protein tumor necrosis factor-*-stimulated protein 6 (TSG-6) promotes early gingival wound healing: an in vivo study. J Periodontol 86:62-71
Zhao, Qingguo; Gregory, Carl A; Lee, Ryang Hwa et al. (2015) MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs. Proc Natl Acad Sci U S A 112:530-5
Hoffman, Michael D; Benoit, Danielle S W (2015) Emulating native periosteum cell population and subsequent paracrine factor production to promote tissue engineered periosteum-mediated allograft healing. Biomaterials 52:426-40
Jung, Youngmee; Ji, HaYeun; Chen, Zaozao et al. (2015) Scaffold-free, Human Mesenchymal Stem Cell-Based Tissue Engineered Blood Vessels. Sci Rep 5:15116
Agarwal, Rachit; González-García, Cristina; Torstrick, Brennan et al. (2015) Simple coating with fibronectin fragment enhances stainless steel screw osseointegration in healthy and osteoporotic rats. Biomaterials 63:137-45
Foskett, Andrea M; Bazhanov, Nikolay; Ti, Xinyu et al. (2014) Phase-directed therapy: TSG-6 targeted to early inflammation improves bleomycin-injured lungs. Am J Physiol Lung Cell Mol Physiol 306:L120-31

Showing the most recent 10 out of 32 publications